Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy
Background: RNA interference therapeutics reduce transthyretin production; however, their effect on hereditary transthyretin amyloid cardiomyopathy (ATTR-CA) remains unclear. We aimed to investigate alterations in technetium-99 m (99mTc)-pyrophosphate (PYP) single-photon emission computed tomography...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | Journal of the Formosan Medical Association |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664624004819 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850208504636243968 |
|---|---|
| author | Yi-Hsin Hung An-Li Yu Yi-Chieh Chen Cheng-Hsuan Tsai Mao-Yuan Su Chia-Tung Shun Hsueh-Wen Hsueh Jimmy Jyh-Ming Juang Ming-Jen Lee Ping-Huei Tseng Chia-Hua Hsu Sung-Tsang Hsieh Chi-Lun Ko Kon-Ping Lin Wen-Chung Yu Mei-Fang Cheng Chi-Chao Chao Yen-Hung Lin |
| author_facet | Yi-Hsin Hung An-Li Yu Yi-Chieh Chen Cheng-Hsuan Tsai Mao-Yuan Su Chia-Tung Shun Hsueh-Wen Hsueh Jimmy Jyh-Ming Juang Ming-Jen Lee Ping-Huei Tseng Chia-Hua Hsu Sung-Tsang Hsieh Chi-Lun Ko Kon-Ping Lin Wen-Chung Yu Mei-Fang Cheng Chi-Chao Chao Yen-Hung Lin |
| author_sort | Yi-Hsin Hung |
| collection | DOAJ |
| description | Background: RNA interference therapeutics reduce transthyretin production; however, their effect on hereditary transthyretin amyloid cardiomyopathy (ATTR-CA) remains unclear. We aimed to investigate alterations in technetium-99 m (99mTc)-pyrophosphate (PYP) single-photon emission computed tomography/computed tomography (SPECT/CT) outcomes in patients receiving patisiran or vutrisiran. Methods: We retrospectively identified individuals with hereditary ATTR-CA who received patisiran or vutrisiran. First and second 99mTc-PYP SPECT/CT data, including visual grading, planar heart to contralateral lung (H/CL) ratio, and volumetric heart to lung (H/L) ratio were assessed. Results: Eight patients with hereditary ATTR-CA were enrolled. Cohort A included four patients who underwent their first 99mTc-PYP SPECT/CT imaging at the initiation of small interfering RNA (siRNA) treatment, while cohort B comprised four patients who had been receiving siRNA treatment before their first 99mTc-PYP SPECT/CT imaging (median duration 1281 days). Overall, there were numerical reductions in planar H/CL ratio (1.7 ± 0.2 to 1.6 ± 0.1, p = 0.050) and a significant improvement in volumetric H/L ratio (4.0 ± 0.9 to 3.5 ± 0.4, p = 0.035). Although without significance, subgroup analysis showed more pronounced changes in cohort A for both planar H/CL ratio and volumetric H/L ratio (−20.1 ± 12.6% and −17.1 ± 11.4%) compared to cohort B (−3.3 ± 11.2% and −4.3 ± 12.7%). Conclusion: Our results demonstrated a significant decrease in volumetric H/L ratio in hereditary ATTR-CA patients receiving RNA interference therapeutics. |
| format | Article |
| id | doaj-art-c70dae52c9674ca89d8b4e0a21091373 |
| institution | OA Journals |
| issn | 0929-6646 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the Formosan Medical Association |
| spelling | doaj-art-c70dae52c9674ca89d8b4e0a210913732025-08-20T02:10:13ZengElsevierJournal of the Formosan Medical Association0929-66462025-04-01124433333910.1016/j.jfma.2024.10.005Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathyYi-Hsin Hung0An-Li Yu1Yi-Chieh Chen2Cheng-Hsuan Tsai3Mao-Yuan Su4Chia-Tung Shun5Hsueh-Wen Hsueh6Jimmy Jyh-Ming Juang7Ming-Jen Lee8Ping-Huei Tseng9Chia-Hua Hsu10Sung-Tsang Hsieh11Chi-Lun Ko12Kon-Ping Lin13Wen-Chung Yu14Mei-Fang Cheng15Chi-Chao Chao16Yen-Hung Lin17Department of Internal Medicine, Division of Cardiology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TaiwanDepartment of Internal Medicine, Division of Cardiology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, Division of Cardiology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, TaiwanDepartment of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TaiwanDepartment of Internal Medicine, Division of Cardiology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; National Taiwan University College of Medicine, Graduate Institute of Clinical Medicine, Taipei, TaiwanDepartment of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan; Department of Medical Imaging and Radiological Technology, Yuanpei University of Medical Technology, Hsinchu, TaiwanDepartment of Forensic Medicine and Pathology, National Taiwan University Hospital, Taipei, TaiwanDepartment of Neurology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TaiwanDepartment of Internal Medicine, Division of Cardiology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TaiwanDepartment of Neurology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TaiwanDepartment of Internal Medicine, Division of Gastroenterology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TaiwanDepartment of Neurology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TaiwanDepartment of Neurology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TaiwanDepartment of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TaiwanDepartment of Neurology, Taipei Veterans General Hospital, Taipei, TaiwanDepartment of Internal Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Cardiovascular Center, Taipei Veterans General Hospital, Taipei, TaiwanDepartment of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Institute of Environmental and Occupational Health Sciences, National Taiwan University, Taipei, Taiwan; Corresponding author. Department of Nuclear Medicine, National Taiwan University Hospital, No. 7, Zhongshan S. Rd., Zhongzheng Dist., Taipei, 100, Taiwan.Department of Neurology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Corresponding author. Department of Neurology, National Taiwan University Hospital, No. 7, Zhongshan S. Rd., Zhongzheng Dist., Taipei, 100, Taiwan.Department of Internal Medicine, Division of Cardiology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TaiwanBackground: RNA interference therapeutics reduce transthyretin production; however, their effect on hereditary transthyretin amyloid cardiomyopathy (ATTR-CA) remains unclear. We aimed to investigate alterations in technetium-99 m (99mTc)-pyrophosphate (PYP) single-photon emission computed tomography/computed tomography (SPECT/CT) outcomes in patients receiving patisiran or vutrisiran. Methods: We retrospectively identified individuals with hereditary ATTR-CA who received patisiran or vutrisiran. First and second 99mTc-PYP SPECT/CT data, including visual grading, planar heart to contralateral lung (H/CL) ratio, and volumetric heart to lung (H/L) ratio were assessed. Results: Eight patients with hereditary ATTR-CA were enrolled. Cohort A included four patients who underwent their first 99mTc-PYP SPECT/CT imaging at the initiation of small interfering RNA (siRNA) treatment, while cohort B comprised four patients who had been receiving siRNA treatment before their first 99mTc-PYP SPECT/CT imaging (median duration 1281 days). Overall, there were numerical reductions in planar H/CL ratio (1.7 ± 0.2 to 1.6 ± 0.1, p = 0.050) and a significant improvement in volumetric H/L ratio (4.0 ± 0.9 to 3.5 ± 0.4, p = 0.035). Although without significance, subgroup analysis showed more pronounced changes in cohort A for both planar H/CL ratio and volumetric H/L ratio (−20.1 ± 12.6% and −17.1 ± 11.4%) compared to cohort B (−3.3 ± 11.2% and −4.3 ± 12.7%). Conclusion: Our results demonstrated a significant decrease in volumetric H/L ratio in hereditary ATTR-CA patients receiving RNA interference therapeutics.http://www.sciencedirect.com/science/article/pii/S092966462400481999mTc‐pyrophosphateHereditary transthyretin amyloidosisRNA interference therapeuticsSingle‐photon emission computed tomography/computed tomography |
| spellingShingle | Yi-Hsin Hung An-Li Yu Yi-Chieh Chen Cheng-Hsuan Tsai Mao-Yuan Su Chia-Tung Shun Hsueh-Wen Hsueh Jimmy Jyh-Ming Juang Ming-Jen Lee Ping-Huei Tseng Chia-Hua Hsu Sung-Tsang Hsieh Chi-Lun Ko Kon-Ping Lin Wen-Chung Yu Mei-Fang Cheng Chi-Chao Chao Yen-Hung Lin Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy Journal of the Formosan Medical Association 99mTc‐pyrophosphate Hereditary transthyretin amyloidosis RNA interference therapeutics Single‐photon emission computed tomography/computed tomography |
| title | Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy |
| title_full | Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy |
| title_fullStr | Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy |
| title_full_unstemmed | Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy |
| title_short | Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy |
| title_sort | use of technetium 99m pyrophosphate single photon emission computed tomography computed tomography in monitoring therapeutic changes of rna interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy |
| topic | 99mTc‐pyrophosphate Hereditary transthyretin amyloidosis RNA interference therapeutics Single‐photon emission computed tomography/computed tomography |
| url | http://www.sciencedirect.com/science/article/pii/S0929664624004819 |
| work_keys_str_mv | AT yihsinhung useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT anliyu useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT yichiehchen useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT chenghsuantsai useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT maoyuansu useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT chiatungshun useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT hsuehwenhsueh useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT jimmyjyhmingjuang useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT mingjenlee useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT pinghueitseng useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT chiahuahsu useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT sungtsanghsieh useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT chilunko useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT konpinglin useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT wenchungyu useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT meifangcheng useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT chichaochao useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy AT yenhunglin useoftechnetium99mpyrophosphatesinglephotonemissioncomputedtomographycomputedtomographyinmonitoringtherapeuticchangesofrnainterferencetherapeuticsinpatientswithhereditarytransthyretinamyloidcardiomyopathy |